Top Markets
Coin of the day
TFF Pharmaceuticals, Inc. TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc.

TFFP
株式のランク #40710
Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals,... Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals, Inc., leverages its proprietary Thin Film Freezing (TFF) technology platform for the advancement and commercialization of therapeutic products across the United States and Australia. A primary emphasis is placed on creating inhaled dry powder formulations to address various pulmonary ailments and disorders. Its two leading drug candidates, both currently in Phase II clinical trials, include TFF Voriconazole Inhalation Powder, designed to combat invasive pulmonary aspergillosis, and TFF Tacrolimus Inhalation Powder, aimed at preventing lung transplant rejection. Beyond these, the company's pipeline features other dry powder products like a cannabidiol substance targeting various epilepsy syndromes, anxiety, insomnia, and pain; an Inhaled SARS-CoV2 Monoclonal Antibody for COVID-19 patients; Niclosamide Inhalation Powder, intended for human tapeworm infections and COVID-19; and a range of other vaccines. Strategic partnerships are also central to its operations, including a licensing arrangement with the University of Texas at Austin for inhaled dry powder drug development, a joint development pact with Augmenta Bioworks, Inc. for the inhaled SARS-CoV2 monoclonal antibody, and a broad licensing and collaboration agreement with UNION therapeutics A/S. Established in 2018, the company maintains its headquarters in Austin, Texas.
株価
$0.065
最終同期: 2025-01-10
時価総額
$94.10K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 TFF Pharmaceuticals, Inc. (TFFP)

カテゴリー

TFF Pharmaceuticals, Inc.(TFFP)の配当利回りの履歴
TFF Pharmaceuticals, Inc.(銘柄コード: TFFP)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
TFF Pharmaceuticals, Inc.(TFFP)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)